

East Bridge Capital Master Fund I Ltd

C/o DMS Corporate Services Limited,
DMS House 20 Genesis Close
Grand Cayman KY1-1108
Cayman Islands

6 September, 2024

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

Fax: +91- 22- 22723121
Tel: +91-22- 22721233/34
Ext. 8013/ 8184/ 8332

Email:
corp.relations@bseindia.com

Dear Sir:


Re: Reporting of sale of shares of Piramal Pharma Ltd

Please find attached the relevant disclosure form as per Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 pursuant to change in shareholding in excess of 2% of the total shareholding in the target company from the date of last disclosure in respect of the above mentioned.

The originals are being couriered to you today.

Thank you for your attention.

Yours faithfully



Cory Pavlik
Director

ANNEXURE-1

Format for Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition


Name of the Target Company (TC)	Piramal Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	East Bridge Capital Master Fund I Ltd. East Bridge Capital Master Fund		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	Bombay Stock Exchange Limited National Stock Exchange of India Limited		
Details of the acquisition/disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights	49,971,950	3.77%	3.77%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
c) Voting rights (VR) otherwise than by equity shares	0	0%	0%
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0	0%	0%
e) Total (a+b+c+d)	49,971,950	3.77%	3.77%
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	2,199,032	0.17%	0.17%
b) VRs acquired/sold otherwise than by equity shares	0	0%	0%
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying	0	0%	0%

voting rights in the TC (specify holding in each category) acquired/sold			
d) Shares encumbered / invoked/released by the acquirer	0	0%	0%
e) Total (a+b+c+d)	2,199,032	0.17%	0.17%
After the acquisition/sale, holding of:			
a) Shares carrying voting rights	47,772,918	3.60%	3.60%
b) Shares encumbered with the acquirer	0	0%	0%
c) VRs otherwise than by equity shares	0	0%	0%
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	0	0%	0%
e) Total (a+b+c+d)	47,772,918	3.60%	3.60%
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer etc.)	Market Transaction		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	06 September 2024		
Equity share capital / total voting capital of the TC before the said acquisition/sale	13,257,481,300		
Equity share capital/ total voting capital of the TC after the said acquisition/sale	13,257,481,300		
Total diluted share/voting capital of the TC after the said acquisition	0		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the acquirer / Authorised Signatory



Place: Boston, MA

Date: September 6, 2024